BAO, Z.,
HAN, Z.,
ZHANG, B.,
YU, Y.,
XU, Z.,
MA, W.,
DING, F.,
ZHANG, L.,
YU, M.,
LIU, S.,
JIN, M.,
YAN, G.,
HUANG, Q.,
WANG, X.,
HUA, B.,
YANG, F.,
LI, Y.,
LIU, Y.,
LI, B.,
WANG, N.,
CAI, B.,
ZAGIDULLIN, N.,
CARVALHO, K. (2019) -actininindifferentiatedhiPSCs.Furthermore,ATOtreatmenthadcausedDNAdamage which was shown in the upregulation of γH2AX, a sensitive marker for DNA
double-strand breaks. Taken
Burtness, B.,
Haddad, R.,
Dinis, J.,
Trigo, J.,
Yokota, T,
De Souza Viana, L.,
Romanov, I.,
Vermorken, J.,
Bourhis, J.,
Tahara, M.,
Martins Segalla, J.G.,
Psyrri, A.,
Vasilevskaya, I.,
Nangia, C.S.,
Chaves-Conde, M.,
Kiyota, N.,
Homma, A.,
Holeckova, P.,
Del Campo, J.M.,
Asarawala, N.,
Nicolau, U.R.,
Rauch, D.,
Even, C.,
Wang, B.,
Gibson, N.,
Ehrnrooth, E.,
Harrington, K.,
Cohen, E.E.W. (2019) . Design, Setting, and Participants: This multicenter, phase 3,
double-blind randomized clinical trial (LUX